ImmunoMRI for Assessment of Tumor-associated Macrophages

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

1. Pathology-proven relapsed/refractory DLBCL
2. Evidence of at least one anatomic site of tumor involvement on most recent prior imaging, e.g. CT, MRI, PET, or ultrasound, reflecting R/R DLBCL.
3. Ability to understand the study goals or outline and to give written informed consent.

Exclusion Criteria:

1. Clinically confirmed pregnancy for women, or breast-feeding women; for pre-menopausal women who do not use hormonal contraception, a pregnancy test with a negative result will be required.
2. Age below the specified minimum of 18 years.
3. Any type of anemia at baseline (due to potentially altered ferumoxytol uptake)
4. Impaired renal function / renal insufficiency
5. Known contraindication to MRI (per MRI Safety Guidelines, or conditions such as claustrophobia)
6. Known hypersensitivity to ferumoxytol or any of its components, or history of allergic reaction to any intravenous iron product.